Literature DB >> 12670411

Melatonin, Circadian Rhythms, and Sleep.

Irina V. Zhdanova1, Valter Tucci.   

Abstract

Experimental data show a close relationship among melatonin, circadian rhythms, and sleep. Low-dose melatonin treatment, increasing circulating melatonin levels to those normally observed at night, promotes sleep onset and sleep maintenance without changing sleep architecture. Melatonin treatment can also advance or delay the phase of the circadian clock if administered in the evening or in the morning, respectively. If used in physiologic doses and at appropriate times, melatonin can be helpful for those suffering from insomnia or circadian rhythm disorders. This may be especially beneficial for individuals with low melatonin production, which is established by measuring individual blood or saliva melatonin levels. However, high melatonin doses (over 0.3 mg) may cause side effects and disrupt the delicate mechanism of the circadian system, dissociating mutually dependent circadian body rhythms. A misleading labeling of the hormone melatonin as a "food supplement" and lack of quality control over melatonin preparations on the market continue to be of serious concern.

Entities:  

Year:  2003        PMID: 12670411     DOI: 10.1007/s11940-003-0013-0

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  20 in total

1.  Effects of low oral doses of melatonin, given 2-4 hours before habitual bedtime, on sleep in normal young humans.

Authors:  I V Zhdanova; R J Wurtman; C Morabito; V R Piotrovska; H J Lynch
Journal:  Sleep       Date:  1996-06       Impact factor: 5.849

2.  Effects of a low dose of melatonin on sleep in children with Angelman syndrome.

Authors:  I V Zhdanova; R J Wurtman; J Wagstaff
Journal:  J Pediatr Endocrinol Metab       Date:  1999 Jan-Feb       Impact factor: 1.634

3.  Complex effects of melatonin on human circadian rhythms in constant dim light.

Authors:  B Middleton; J Arendt; B M Stone
Journal:  J Biol Rhythms       Date:  1997-10       Impact factor: 3.182

4.  Influence of beta-blockers on melatonin release.

Authors:  K Stoschitzky; A Sakotnik; P Lercher; R Zweiker; R Maier; P Liebmann; W Lindner
Journal:  Eur J Clin Pharmacol       Date:  1999-04       Impact factor: 2.953

5.  Increased bioavailability of oral melatonin after fluvoxamine coadministration.

Authors:  S Härtter; M Grözinger; H Weigmann; J Röschke; C Hiemke
Journal:  Clin Pharmacol Ther       Date:  2000-01       Impact factor: 6.875

6.  [Angelman syndrome: physical characteristics and behavioural phenotype in 37 patients with confirmed genetic diagnosis].

Authors:  M Galván-Manso; J Campistol; E Monros; P Póo; A M Vernet; M Pineda; A Sans; J Colomer; J J Conill; F X Sanmartí
Journal:  Rev Neurol       Date:  2002 Sep 1-15       Impact factor: 0.870

7.  [Melatonin lowers the threshold of light sensitivity of the human retina].

Authors:  E B Arushanian; K B Ovanesov
Journal:  Eksp Klin Farmakol       Date:  1999 Mar-Apr

8.  Hypnotic activity of melatonin.

Authors:  B M Stone; C Turner; S L Mills; A N Nicholson
Journal:  Sleep       Date:  2000-08-01       Impact factor: 5.849

9.  Effect of melatonin on sleep microstructure: preliminary results in healthy subjects.

Authors:  L Ferini-Strambi; M Zucconi; G Biella; B Stankov; F Fraschini; A Oldani; S Smirne
Journal:  Sleep       Date:  1993-12       Impact factor: 5.849

10.  Effect of fluoxetine on melatonin in patients with seasonal affective disorder and matched controls.

Authors:  P A Childs; I Rodin; N J Martin; N H Allen; L Plaskett; P J Smythe; C Thompson
Journal:  Br J Psychiatry       Date:  1995-02       Impact factor: 9.319

View more
  8 in total

1.  Sleep physiology, abnormal States, and therapeutic interventions.

Authors:  Alvah T Wickboldt; Alex F Bowen; Aaron J Kaye; Adam M Kaye; Franklin Rivera Bueno; Alan D Kaye
Journal:  Ochsner J       Date:  2012

Review 2.  Adverse Events Associated with Melatonin for the Treatment of Primary or Secondary Sleep Disorders: A Systematic Review.

Authors:  Frank M C Besag; Michael J Vasey; Kim S J Lao; Ian C K Wong
Journal:  CNS Drugs       Date:  2019-12       Impact factor: 5.749

3.  Association of Fatigue With Sleep Duration and Bedtime During the Third Trimester.

Authors:  Duo Ma; Yimin Kang; Denglan Wang; Haoxiong Chen; Ligang Shan; Chun Song; Yanlong Liu; Fan Wang; Hui Li
Journal:  Front Psychiatry       Date:  2022-07-06       Impact factor: 5.435

4.  Melatonin Pretreatment Protects Against Status epilepticus, Glutamate Transport, and Oxidative Stress Induced by Kainic Acid in Zebrafish.

Authors:  Ana Caroline Salvador de Farias; Karolyne de Pieri Pickler; Henrique Teza Bernardo; Samira Leila Baldin; Eduardo Ronconi Dondossola; Eduardo Pacheco Rico
Journal:  Mol Neurobiol       Date:  2021-10-19       Impact factor: 5.682

Review 5.  Role of the melatonin system in the control of sleep: therapeutic implications.

Authors:  Seithikurippu R Pandi-Perumal; Venkatramanujan Srinivasan; D Warren Spence; Daniel P Cardinali
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

Review 6.  Serotonin-kynurenine hypothesis of depression: historical overview and recent developments.

Authors:  Gregory Oxenkrug
Journal:  Curr Drug Targets       Date:  2013-05-01       Impact factor: 3.465

7.  A Novel Function of the Lysophosphatidic Acid Receptor 3 (LPAR3) Gene in Zebrafish on Modulating Anxiety, Circadian Rhythm Locomotor Activity, and Short-Term Memory.

Authors:  Yu-Nung Lin; Gilbert Audira; Nemi Malhotra; Nguyen Thi Ngoc Anh; Petrus Siregar; Jen-Her Lu; Hsinyu Lee; Chung-Der Hsiao
Journal:  Int J Mol Sci       Date:  2020-04-18       Impact factor: 5.923

8.  Enhanced anti-angiogenic activity of novel melatonin-like agents.

Authors:  Su Jung Hwang; Yeonghun Jung; Ye-Seul Song; Suryeon Park; Yohan Park; Hyo-Jong Lee
Journal:  J Pineal Res       Date:  2021-05-13       Impact factor: 13.007

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.